MARKET

ARVN

ARVN

Arvinas
NASDAQ
11.90
-0.44
-3.57%
After Hours: 11.90 0 0.00% 17:40 12/16 EST
OPEN
12.31
PREV CLOSE
12.34
HIGH
12.44
LOW
11.61
VOLUME
1.01M
TURNOVER
--
52 WEEK HIGH
21.00
52 WEEK LOW
5.90
MARKET CAP
764.27M
P/E (TTM)
-14.7844
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARVN last week (1208-1212)?
Weekly Report · 1d ago
Arvinas Reveals Promising Preclinical Data for ARV-393
TipRanks · 12/08 11:55
Reported Saturday, Arvinas Reports ARV-393 Plus Glofitamab Delivers Significantly Enhanced Tumor Growth Inhibition And Increased Tumor Regression Versus Either Agent Alone
Benzinga · 12/08 09:25
Weekly Report: what happened at ARVN last week (1201-1205)?
Weekly Report · 12/08 09:20
Arvinas announces preclinical data for ARV-393
TipRanks · 12/07 18:10
Arvinas Announces Phase 1 Trial of ARV-393 and Glofitamab Combination for Lymphoma
Reuters · 12/06 13:05
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
Barchart · 12/06 07:05
Arvinas Holding Company (ARVN) Receives a Buy from Piper Sandler
TipRanks · 12/05 12:41
More
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Webull offers Arvinas Inc stock information, including NASDAQ: ARVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARVN stock methods without spending real money on the virtual paper trading platform.